UACT and KEI Comments to NIH Regarding Exclusive License of CAR therapy for Cancer to Syncopation
On Friday July 9, 2021, the Union for Affordable Cancer Treatment (UACT) and Knowledge Ecology International (KEI) filed joint comments with the National Institutes of Health (NIH) regarding a prospective exclusive license for a cancer therapy technology. The Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies” (86 FR 33326), outlined that the technology is to be licensed to Syncopation Life Sciences Inc. (Syncopation), which is based in Palo Alto, CA. The technology is an anti-CD22 CAR therapy, which has been shown to be effective inRead More →